Send to

Choose Destination
Drug Metab Lett. 2007 Apr;1(2):153-61.

Disposition of vorinostat, a novel histone deacetylase inhibitor and anticancer agent, in preclinical species.

Author information

Department of Drug Metabolism, Merck Research Laboratories, West Point, Pennsylvania 19486, USA.


The disposition of vorinostat, an anticancer agent, was investigated in rats and dogs. Vorinostat possessed high serum clearance, a short elimination half-life and low oral bioavailability in both species. The renal route played an important role in the elimination of drug-related material and vorinostat was eliminated primarily by metabolic biotransformation.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Bentham Science Publishers Ltd.
Loading ...
Support Center